The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
because they're just helping those neurons communicate in the case of xenepazil and glantamine and ribostigmine they're you know cholinesterase inhibitors and then there's mementine which is an nmda receptor antagonist that normalizes levels of glutamate but they're just they're helping with neurotransmitters and they're not targeting the underlying pathology of amyloid and tau
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the symptomatic treatments are ones that you know can help slow cognitive decline or help improve memory and thinking but are not targeting the underlying disease process so all the drugs that we currently have on the market are ones that are symptomatic treatments because they're just helping those neurons communicate in the case of xenepazil and glantamine and ribostigmine they're you know cholinesterase inhibitors and then there's mementine which is an nmda receptor antagonist that that normalizes levels of glutamate but they're just they're helping with neurotransmitters and they're not um targeting the underlying pathology of amyloid and tau